Gibco™ Human IL-31 Recombinant Protein 

Description

Carrier-Free Reconstitution: Centrifuge the vial briefly, before opening to bring the contents to the bottom. Reconstitute the lyophilized protein in sterile distilled water to a concentration of 0.1-1.0 mg/mL. Do not vortex. For extended storage, dilute the constituted protein in buffered solution containing carrier protein, such as PBS with 0.1% BSA. Apportion the diluted protein into working aliquots, and store at ≤-20°C to -80°C. Storage: The lyophilized protein is stable at room temperature for 1 month, but should be kept at -20°C to -80°C for long-term storage, preferably desiccated. The reconstituted protein is stable at 2-8°C for up to 1 week. Working aliquots stored with a carrier protein are stable for at least 3 months at ≤-20°C to ≤-80°C. Avoid repeated freeze-thaw cycles.

Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.